1. Academic Validation
  2. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence

Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence

  • Cell Metab. 2018 Mar 6;27(3):529-547. doi: 10.1016/j.cmet.2018.02.011.
Luis Rajman 1 Karolina Chwalek 1 David A Sinclair 2
Affiliations

Affiliations

  • 1 Paul F. Glenn Center for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
  • 2 Paul F. Glenn Center for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Laboratory for Ageing Research, Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: [email protected].
Abstract

Nicotinamide adenine dinucleotide (NAD), the cell's hydrogen carrier for redox Enzymes, is well known for its role in redox reactions. More recently, it has emerged as a signaling molecule. By modulating NAD+-sensing Enzymes, NAD+ controls hundreds of key processes from energy metabolism to cell survival, rising and falling depending on food intake, exercise, and the time of day. NAD+ levels steadily decline with age, resulting in altered metabolism and increased disease susceptibility. Restoration of NAD+ levels in old or diseased Animals can promote health and extend lifespan, prompting a search for safe and efficacious NAD-boosting molecules that hold the promise of increasing the body's resilience, not just to one disease, but to many, thereby extending healthy human lifespan.

Keywords

CD38; PARP1; STAC; aging; cancer; cardiovascular disease; chromatin; epigenetics; inflammation; nicotinamide mononucleotide; nicotinamide riboside; sirtuins.

Figures
Products